Clinical Trials Sponsored by Ferring SAU

Total 12376 results

Ferring Pharmaceuticals

Completed

Effectiveness of Cortiment® in Patients With Ulcerative Colitis (CORE Practice)

Ulcerative Colitis

Canada, Germany, Ireland, Italy, Netherlands, Poland, Sweden, United Kingdom
Ferring Pharmaceuticals

Completed

Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Female Subjects

Nocturia

Japan
Ferring Pharmaceuticals

Completed

A Randomised Trial Using Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) in Women Undergoing Controlled Ovarian Stimulation (FASHION)

Infertility

Brazil
Ferring Pharmaceuticals

Completed

Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer

Prostate Cancer

China
Ferring Pharmaceuticals

Completed

A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel in Adult Hypogonadal Males

Adult Male Hypogonadism

United States
Ferring Pharmaceuticals

Completed

An Efficacy and Safety Study of PENTASA in Chinese Patients With Left-sided Active Ulcerative Colitis Followed by a 24-Week Open-Label Extension Phase

Ulcerative Colitis

China
Ferring Pharmaceuticals

Completed

An Explorative Prospective Observational Study to Describe Morphokinetic De-selection Parameters in Human Embryos

Infertility

Denmark
Ferring Pharmaceuticals

Completed

Documentation of the Efficacy of Desmopressin Within the Context of Surgical Procedures (RAPID)

Platelet Dysfunction

Germany
Ferring Pharmaceuticals

Completed

A Study to Investigate Interleukin-6 (IL-6) and IL-6/Soluble IL-6 Receptor (sIL-6R) Complex Levels in Subjects With Active Inflammatory Bowel Disease

Inflammatory Bowel Disease

Denmark, Sweden
Ferring Pharmaceuticals

Completed

A Trial Comparing the PICOPREP Tailored Dosing Schedule to the PICOPREP Day-before Dosing Schedule for Colon Cleansing in Preparation for Colonoscopy (OPTIMA)

Bowel Cleansing

France, Germany, Netherlands
Ferring Pharmaceuticals

Terminated

Monitoring of Safety and Tolerance of PICOPREP in Clinical Practice

Bowel Cleanliness

Czech Republic
Ferring Pharmaceuticals

Completed

An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults

Nocturia

United States, Canada
Ferring Pharmaceuticals

Terminated

Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

Sweden, Canada, Hungary, United States, Brazil, South Africa, Czech Republic, Germany, Mexico, Poland, Slovakia, United Kingdom
Ferring Pharmaceuticals

Terminated

26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

Israel, Belgium, United States, United Kingdom, Germany, Poland, Brazil, Canada, Czech Republic, South Africa
Ferring Pharmaceuticals

Completed

Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome

Hyperphagia in Prader-Willi Syndrome

United States
Ferring Pharmaceuticals

Completed

Evaluation of Efficacy and Safety of Highly Purified Urofollitropin in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program

Infertility

China
Ferring Pharmaceuticals

Terminated

A Degarelix Trial in Patients With Prostate Cancer

Prostate Cancer

United States, Netherlands, United Kingdom, Hungary, Belgium, Czech Republic, Finland, Germany, Mexico, Poland, Romania, Ukraine, Canada
Ferring Pharmaceuticals

Withdrawn

Elobixibat Colonic Motor Function Study

Chronic Idiopathic Constipation

United States
Ferring Pharmaceuticals

Completed

A Follow-up Study to Examine the Presence of Anti-human Growth Hormone Antibodies Following a Study (FE 999905 CS07) of Zomacton in Children With Growth Hormone Deficiency

Idiopathic Growth Hormone Deficiency

Hungary, India, Israel, Poland, Romania, Russian Federation, Ukraine
Ferring Pharmaceuticals

Completed

Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia.

BPH

Germany
Ferring Pharmaceuticals

Completed

An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer

Prostate Cancer

Belgium, Germany, Hungary, Netherlands, Romania, Russian Federation, South Africa
Ferring Pharmaceuticals

Completed

Mesalazine 4g Once Daily Versus 4g in Two Divided Doses in Active Ulcerative Colitis.

Ulcerative Colitis

United Kingdom, France, Belgium, Netherlands
Ferring Pharmaceuticals

Completed

Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery (EXPEDITE)

Induction of Labor | Cervical Ripening | Reducing Time to Vaginal Delivery

United States
Ferring Pharmaceuticals

Completed

A Study of Degarelix in Taiwanese Patients With Prostate Cancer

Prostate Cancer

Taiwan
Ferring Pharmaceuticals

Completed

A Study of Minirin Melt in Patients With Nocturia

Nocturia

Czech Republic
Ferring Pharmaceuticals

Completed

Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult Men (NOC)

Nocturia

Japan
Ferring Pharmaceuticals

Completed

A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy

Prostate Cancer

United States, Netherlands, Hungary, Czech Republic, Germany, Mexico, Romania, Russian Federation, Ukraine, Canada, Puerto Rico, United Kingdom
Ferring Pharmaceuticals

Completed

Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Split Dose PicoPrep

Bowel Preparation

United States
Ferring Pharmaceuticals

Completed

Investigation of PICOPREP and PEG-ELS for Bowel Preparation for Colonoscopy

Colonoscopy

China
Ferring Pharmaceuticals

Completed

Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer

Prostate Cancer

Germany
Ferring Pharmaceuticals

Terminated

CNI-1493 for Treatment of Moderate to Severe Crohn's Disease (CD02)

Crohn Disease

United States
Ferring Pharmaceuticals

Withdrawn

Pharmacokinetics and Safety of the 100 Mcg Misoprostol Vaginal Insert (MVI 100) (Miso-Obs-203)

Induction of Labor | Cervical Ripening

United States
Ferring Pharmaceuticals

Terminated

Study of Effects and of Modifications in Apoptosis Regulators Observed After Stopping 5-ASA Treatment in Patients With Inactive Ulcerative Colitis

Ulcerative Colitis

France
Ferring Pharmaceuticals

Completed

A Study of Terlipressin in Patients With Hepatorenal Syndrome Type 1 (HRS)

Hepatorenal Syndrome Type 1

Japan
Ferring Pharmaceuticals

Completed

A Study of PICOPREP in Patients Needed to Clean the Bowel Prior to X-ray Examination, Endoscopy or Surgery.

Bowel Cleanliness

Czech Republic
Ferring Pharmaceuticals

Completed

Investigation of KLYX in Patients With Constipation

Constipation

China
Ferring Pharmaceuticals

Completed

Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)

Infertility | Polycystic Ovarian Syndrome

United States
Ferring Pharmaceuticals

Completed

A Study of the Efficacy and Safety of EUFLEXXA™ for Treatment of Painful Osteoarthritis of the Knee

Osteoarthritis, Knee

United States
Ferring Pharmaceuticals

Completed

A Proof of Concept Study Assessing the Effect of Four Different Single Bolus Intravenous Doses of FE200440 and Placebo on Stopping Preterm Labor

Premature Birth | Labor, Premature

Finland, Belgium, Czech Republic, Lithuania, Poland, Romania
Ferring Pharmaceuticals

Completed

Study With Two Different Doses of Desmopressin Orally Lyophilisate Tablet With Nocturnal Enuresis (PNE)

Nocturnal Enuresis

Japan
Ferring Pharmaceuticals

Completed

MENOPUR® Versus FOLLISTIM®

Infertility

United States
Ferring Pharmaceuticals

Completed

Retrospective Data Analysis in Crohn's Disease (Crohn 2)

Crohn's Disease

Germany
Ferring Pharmaceuticals

Terminated

Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients

Prostate Cancer
Ferring Pharmaceuticals

Completed

Study Assessing the Effect of 3-week Treatment With One of Three Oral Doses of Quinagolide

Ovarian Hyperstimulation Syndrome

Spain
Ferring Pharmaceuticals

Completed

A Study of Oral Desmopressin in Previously Untreated Children Aged 5 to 15 Years With Primary Nocturnal Enuresis (DRIP)

Nocturnal Enuresis

France
Ferring Pharmaceuticals

Completed

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH

InFertility

United States
Ferring Pharmaceuticals

Completed

Desmopressin Response in the Young (DRY)

Primary Nocturnal Enuresis

Canada
Ferring Pharmaceuticals

Completed

Efficacy and Safety of Desmopressin (Nocturin®) 0.1 mg Tablets in Treatment of Nocturia in Participants With Benign Prostate Syndrome (BPS)

Nocturia Associated With Nocturnal Polyuria

Germany
Ferring Pharmaceuticals

Completed

Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy

Prostate Cancer

United States, Czech Republic, Hungary, Romania, Canada
Ferring Pharmaceuticals

Withdrawn

Open-Label, Randomised Parallel-Group Study

Prostate Cancer

3

Subscribe